Genesis Receives Funding Commitment for New Subsidiary, Prepares New Share-Purchase Plan

Genesis said that it has received a commitment from an undisclosed group for an investment in the subsidiary, which would develop its single-stranded RNAi technology. But with about two months worth of cash in the bank, the company is asking shareholders to make new equity investments.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.